Level 1: eLearning

ESMIT Live Webinar series

Easily accessible from the comfort of your own home – Get the best of ESMIT education without travelling!

Live webinars are condensed pieces of live, high-quality education which include theoretical presentations, case-based teachings, and a lot of interaction between our facilitators and our participants.

Through this series of free live webinars, experts in the field of nuclear medicine will share their knowledge about various topics in an interactive online setting accessible from all over the world.

  • In our 2020 offer, this series includes 9 webinars, written and facilitated in English.
  • Each live webinar is limited to 250 participants.
  • After the live event has taken place, the recording will be accessible for free on our eLearning platform. You can access the eLearning materials by logging in with your personal username and password or easily creating a new confidential account.
  • Participants of the live webinar series will receive CME credits.

 

The Cardiology Webinars are provided by the European Association of Nuclear Medicine (EANM) in collaboration with the European Association of Cardiovascular Imaging (EACVI) to prepare for the EAN/EAVCI Certification exam in Nuclear Cardiology.
Further information can be found online:
https://www.escardio.org/Education/Career-Development/Certification/Nuclear-Cardiology
Ein Bild, das Zeichnung enthält. Automatisch generierte Beschreibung

 

ESMIT 2020 Live Webinar Series

Neurology FDG PET and Structural MRI in Alzheimer and Fronto-temporal Dementia June 10 12:00 Registration closed
Cardiology Principles and Indications for Stress MPS June 10 14:00 Registration closed 
Oncology Pitfalls and Artifacts in Prostate Cancer PET Imaging  June 12 14:00 Registration closed
Neurology Molecular Imaging in Dementia with Parkinsonism July 9 12:00 Register now! 
Cardiology SPECT-MPI: Protocols, Pearls and Pitfalls July 9 14:00 Register now! 
Oncology How to report PSMA PET in Prostate Cancer. An Introduction to “E-PSMA: The EANM standardized Reporting Guidelines v1.0 for PSMY PET/CT” July 10 14:00 Register now! 
Neurology Amyloid PET in Dementia Sept. 10 12:00 Registration opening soon
Oncology PSMA Imaging in Advanced Prostate Cancer. From PET to PSMA Radio-Ligand Therapy Sept. 11 12:00 Registration opening soon
Cardiology Nuclear Medicine Diagnostics and Monitoring in Large Vessel Vasculitis and Cardiac Amyloidosis Sept. 11 14:00 Registration opening soon

 

Upcoming ESMIT Live Webinars 


Molecular Imaging in Dementia with Parkinsonism

July 9, 2020 – 12:00 (CEST)

Speaker: Silvia Morbelli
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 


Content

The talk will discuss the clinical use of brain PET and SPECT in Parkinson’s disease (PD) and atypical parkinsonisms associated with dementia. Both the clinical Utility Molecular Imaging in facilitating the differential diagnosis of common forms of parkinsonism as well as its role in the risk stratification of these patients. Accordingly studies on dementia with lewy bodies (DLB), PD, progressive supranuclear palsy (PSP) syndromes, and corticobasal syndrome (CBS) we’ll be discussed. Aspects related to the role of brain PET and SPECT in prodromal stages of disease will be coverd.

 

Learning objectives

  • To learn about the clinical utility of  FDG-PET and DAT SPECT  to support the diagnosis of parkinsonian syndromes associated with dementia
  • To understand the role of molecular imaging in predicting the risk of convension to dementia in patients with parkinsonism and in particular in PD patients.
  • To appreciate the added value of molecular imaging in prodromal stages of DLB and PD

 

Suggested readings

  • Nobili F, Arbizu J, Bouwman F, Drzezga A, Filippi M, Nestor P, et al. EAN-EANM recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 20181
  • Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545
  • KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm. 2018;125(4):615–650. doi: 10.1007/s00702-017-1821-9
  • Research criteria for the diagnosis of prodromal dementia with Lewy bodies. McKeith IG, Ferman TJ, et al ; prodromal DLB Diagnostic Study Group. Neurology. 2020 Apr 28;94(17):743-755.
  • Morbelli, S., Esposito, G., Arbizu, J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes

SPECT-MPI: Protocols, Pearls and Pitfalls

July 9, 2020 – 14:00 (CEST)

Speakers: Antti Saraste
Fabien Hyafil
Moderator: Christoph Rischpler
Target audience: Nuclear Medicine physicians, Cardiologists, physicists, radiopharmacists
 


 

Content

  • Implementing gated SPECT
  • CAD diagnosis SPECT/CT
  • Viability detection SPECT
  • Artifacts
  • Challenges in MPI: pearls and pitfalls

 

Learning objectives

The aim of this webinar will be to give an overview on how to perform, analyze and write reports for SPECT-MPI.


How to report PSMA PET in Prostate Cancer:
An Introduction to “E-PSMA: The EANM standardized Reporting Guidelines v1.0 for PSMA PET/CT”

July 10, 2020 – 14:00 (CEST)

Speaker: Francesco Ceci
Moderator: Patrick Pilkington
Target audience: Nuclear Medicine Physicians, urologist, radiation oncologist, residents
 


Content

This live webinar will discuss the standardization of the clinical report for PSMA PET in Prostate Cancer, in according to the most recent guidelines released by the EANM.

 

Learning objectives

This lecture will have as main objective to provide an overview about the new guidelines for reporting PSMA PET as suggested by the EANM. The audience will be introduced to the structured report for PSMA PET and will understand how to provide a report in accordance to EANM guidelines. Finally, hints and tips will be given regarding how to avoid common mistakes in PSMA PET images reading and how to interpret the most common findings that represent potential pitfalls.

 

Suggested readings

  • E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2020. [Under Review].
  • Eiber M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT [published correction appears in J Nucl Med. 2018 Jun;59(6):992]. J Nucl Med. 2018;59(3):469‐478.
  • Ceci, F., Fanti, S. Standardisation of PSMA images interpretation: why do we need it?. Clin Transl Imaging 6, 331–333 (2018). https://doi.org/10.1007/s40336-018-0301-z.

Amyloid PET in Dementia

September 10, 2020 – 12:00 (CEST)

Speaker: Henryk Barthel
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

 

Content

This webinar will discuss the available tracers to image amyloid pathology by PET, and the respective image analysis techniques. It will also provide the current clinical indications for amyloid imaging, together with future trends in this regard. Also, some amyloid PET imaging cases will be discussed.

 

Learning objectives

The aim of this webinar is

  • To provide an overview on the different amyloid PET tracers/respective analysis rules
  • To teach current appropriate use criteria for amyloid PET imaging
  • To increase amyloid PET reading confidence

 

Suggested readings

  • Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce. Alzheimers Dement. 2013 Jan;9(1):e-1-16.
  • SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.  Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K. J Nucl Med. 2016 Aug;57(8):1316-22
  • Yes we can analyse amyloid images – Now What? Barthel H, Seibyl J, Sabri O. Eur J Nucl Med Mol Imaging. 2017 May;44(5):822-824.
  • Proven validity and management impact of amyloid imaging in Alzheimer’s disease-repetita juvant. Barthel H, Arbizu J, Drzezga A, Garibotto V, Lammertsma AA, Morbelli S; EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging. 2020 Mar 4. doi: 10.1007/s00259-020-04742-w

PSMA Imaging in Advanced Prostate Cancer. From PET to PSMA Radio-Ligand Therapy

September 11, 2020 – 12:00 (CEST)

Speaker: Benedikt Feuerecker
Moderators: Francesco Ceci
Patrick Pilkington
Target audience: Nuclear Medicine Physicians, urologist, radiation oncologist, oncologist, residents
 

Content

In this live webinar we will discuss the role of PSMA PET imaging in advanced prostate cancer. More in detail this lecture will give recommendations regarding the proper selection of patients suitable for PSMA based radioligand therapy.

 

Learning objectives

  • To understand how to interpret PSMA PET scans in advanced metastatic patients
  • To understand which PET parameters should be taken into consideration prior to radio-ligand therapy
  • To understand possible sources of error (e.g. PSMA negative lesions or missmatch between PSMA and FDG PET)

 

Suggested readings

  • Kratochwil C, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536‐2544.
  • Hofman MS, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825‐833.
  • Kratochwil C, Haberkorn U, Giesel FL. Radionuclide Therapy of Metastatic Prostate Cancer. Semin Nucl Med. 2019;49(4):313‐325.
  • Fendler WP, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(24):7448‐7454. doi:10.1158/1078-0432.CCR-19-1050

Nuclear Medicine Diagnostics and Monitoring in Large Vessel Vasculitis and Cardiac Amyloidosis

September 11, 2020 – 14:00 (CEST)

Speakers: Olivier Gheysen
Riemer Slart
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, residents NM, imaging-cardiologists, imaging-rheumatologists
 

 

Content

Large vessel vasculitis (LVV) is a disease characterized by inflammation of the larger arteries with two main variants Takayasu arteritis (TA) and giant cell arteritis (GCA). Both entities differ in terms of age onset, ethnic distribution and affected vascular territories, but share overlap in the histopathology of inflammatory lesions. In addition, GCA belongs to a disease spectrum with polymyalgia rheumatica with both entities often present within the same patient. Nowadays, FDG-PET/CT plays a crucial role in the diagnosis of patients with LVV or the co-existence of LVV and PMR. It is important to early establish the diagnosis of LVV to timely initiate therapy in order to prevent late complications such as stenoses and aneurysms.  Since FDG-PET is a whole-body imaging technique, it provides information of the vessels involved in the disease process and may assist in the differential diagnosis between PMR and other rheumatological disorders such as elderly-onset rheumatoid arthritis based on the inflammatory patterns. In additon to diagnosis, there is emerging evidence that FDG-PET is a suitable modality to assess therapy efficacy which may be important to evaluate novel anti-inflammatory drugs. The introduction of PET/MR may allow simultaneous information on vessel wall inflammation and morphology, which may be advantageous for assessing cranial arteries, but this requires further investigations. Finally, novel tracer development e.g. targeting interleukins may also play a role in the future.

Cardiac amyloidosis (CA), commonly resulting from deposition of misfolded immunoglobulin light chain (AL) or transthyretin (ATTR) protein, is an underestimated cause of heart failure. ATTR has gained increasing attention in recent years and can be divided into a hereditary type (ATTRv) and a wild-type (ATTRwt). Accurate and early diagnosis of heart failure as a result of CA has major implications on prognosis and treatment, using echo and MRI in the first line. Molecular imaging with PET and SPECT nowadays play a critical role in the diagnosis, identification and distinction between ATTR and AL type CA. Bone scintigraphy is an important non-invasive tool to diagnose cardiac amyloidosis due to ATTR (either ATTRv or ATTRwt). Additionally, the innervation agent 123I-MIBG accumulates in vesicles in sympathetic nerve endings close to myocardial cells and the reduced uptake and increased loss reflects myocardial cell damage caused by amyloid. More specific PET-imaging tracers in amyloidosis selectively bind to β-amyloid plaques. Current and new treatments are targeted at reducing the production or stabilisation of the precursor protein or aiming at promoting amyloid removal and thereby aim to stop or slow down further accumulation of CA. Molecular imaging should be able to visualize regression of CA under these new treatment regimens, but data are lacking at this moment. For diagnostic considerations, specific target imaging using hybrid or multimodality techniques such as PET/MR definitely will play a role in the future.

 

Learning objectives 

  • Background information of large vessel vasculitis (LVV)/polymyalgia rheumatica (PMR) and cardiac amyloidosis (CA), including the different types, and it’s disease burden.
  • The role of non-invasive imaging in the diagnostic work-up of LVV and CA.
  • Details of FDG PET/CT in LVV/PMR and bone agent imaging in CA, including imaging protocol, scoring, and interpretation, using the new consensus recommendations.
  • Overview of novel PET imaging in CA. • New therapy approaches for managing patients with LVV/CA

 

Suggested readings

  • doi: 10.1007/s12350-019-01760-6
  • doi: 10.1007/s12350-019-01761-5
  • doi: 10.1007/s00259-018-3973-8
  • EANM 2018 & 2019 CME LVV and CA

 

 

Past ESMIT Live Webinars 

The recordings of the following webinars are available on the ESMIT eLearning Platform.


FDG PET and Structural MRI in Alzheimer and Dementia

June 10, 2020 – 12:00 (CEST)

Speaker: Diego Cecchin
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

Content

This webinar will show typical 18F-FDG patterns of brain hypometabolism in the context of neurodegenerative disease and in particular regarding Alzheimer disease (AD) and fronto-temporal dementia (FTD). Moreover the talk will discuss main structural (MRI) alterations in neurodegeneration with particular attention to AD and FTD. Common (combined or not) hypometabolism and structural alterations will be presented using clinical 18F-FDG PET/MR cases. Finally proteinopaties concerning AD and FTD will be briefly discussed.

 

Learning objectives

  • Recognize common structural signs of neurodegeneration in MRI
  • Recognize common patterns of hypometabolism in 18FDG PET in AD and FTD
  • Understand which proteinopaty underlie AD and FTD

 

Suggested readings

  • A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.Neurology. 2016 Aug 2;87(5):539-47. doi:10.1212/WNL.0000000000002923. Epub 2016 Jul 1.
    PMID: 27371494
  • Alzheimer’s disease.
    Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.Lancet. 2016 Jul 30;388(10043):505-17.
    doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24.
    PMID: 26921134 Review.
  • FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease.
    Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S.Brain. 2007 Oct;130(Pt 10):2616-35.
    doi: 10.1093/brain/awm177. Epub 2007 Aug 18.
    PMID: 17704526

Principles and Indications for Stress MPS

June 10, 2020 – 14:00 (CEST)

Speakers: Alessia Gimelli
Eliana Reyes
Moderator: Christoph Rischpler
 

Content

This webinar introduces the basic principles that govern the clinical applications of stress MPS. The indications for MPS are discussed in the context of contemporary imaging technology and protocols, including the use of solid-state gamma-camera systems, the practicalities of regadenoson stress, and the added value of quantitative myocardial perfusion

 

Learning objectives

At the end of this webinar, participants should be able to:

  • Understand the principles underlying the use of MPS for the assessment of coronary artery disease
  • Appreciate the current indications for stress MPS
  • Become familiar with imaging & stress MPS protocols and their importance in clinical practice and service delivery standardisation
  • Recognise the effect of the most advances in stress MPS on clinical practice


Pitfalls and Artefacts in Prostate Cancer PET Imaging 

June 12, 2020 – 14:00 (CEST)

Speaker: Paolo Castellucci
Moderators: Francesco Ceci
Patrick Pilkington
Target audience Nuclear Medicine Physicians, urologist, radiation oncologist, residents
 

Content

In this live webinar we discuss pitfalls, different biodistribution and artefacts for PET/CT imaging in Pca. The lecture will focus on 68Ga-PSMA and 18F-PSMA PET and Fluciclovine PET. Clinical cases will be provided to support the lecture.

 

Learning objectives

  • To understand the different biodistribution among different PSMA variants
  • To understand possible sources of pitfall in PSMA imaging, both considering false positive and false negative findings
  • To introduce the basic concepts and the most common pitfalls in Fluciclovine PET

 

Suggested readings

  • Sheikhbahaei S,  et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117-36. 39.
  • Rischpler C,  et al. 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine. 2018;59(9):1406-11.
  • Rauscher I, et al. Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2019.
  • Nanni C, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. Eur J Nucl Med Mol Imaging. 2020;47(3):579‐591.
This website uses cookies. Learn more